Investigation Launched by Faruqi & Faruqi for Tvardi Therapeutics Shareholders

Tvardi Therapeutics Shareholder Investigation

In recent news, Faruqi & Faruqi, LLP, a prominent national securities law firm, has begun investigating potential claims on behalf of shareholders of Tvardi Therapeutics, Inc. (NASDAQ TVRD). This comes in response to significant losses experienced by investors following a distressing decline in the company’s stock price.

On October 13, 2025, shares of Tvardi experienced a staggering plunge of over 80% after the release of disappointing preliminary data from the Phase 2 REVERT clinical trial concerning TTI-101, a treatment aimed at idiopathic pulmonary fibrosis. The trial, designed to assess both safety and pharmacokinetics while also exploring outcomes related to lung function, did not meet its predefined goals. The findings indicated that the study's initial safety data and dates related to efficacy showed insufficient support for the treatment's viability.

The preliminary analysis revealed that the baseline characteristics of the participants were comparably similar throughout the treatment arms. However, a notable distinction emerged — the percent predicted Forced Vital Capacity (FVC) was found to be lower among patients receiving placebo compared to those on the TTI-101 treatment, hinting at a lack of efficacy in the therapy under review.

Investors who suffered from these significant financial losses are being encouraged to connect directly with James (Josh) Wilson, a partner at Faruqi & Faruqi, for discussions regarding potential legal rights and options available to them. Josh Wilson can be reached via phone at 877-247-4292 or 212-983-9330 (Ext. 1310). Further information can also be sought out on the firm’s official website at www.faruqilaw.com/TVRD.

Faruqi & Faruqi has a notable history of recovering large sums for investors since its establishment in 1995, highlighting the firm's commitment to protect and advocate for shareholder rights. As the investigation unfolds, updates will be shared on their social media channels, including LinkedIn and Facebook.

For investors in Tvardi Therapeutics, this is a crucial moment that necessitates proactive measures in light of the recent developments affecting their investments. Understanding the legal implications and the potential for recovery could be pivotal for those affected by the company’s recent downturn. Time is of the essence, and stakeholders are urged to act promptly to explore their available options.

In conclusion, the upcoming period may prove vital not only for individual investors seeking to reclaim financial losses but also for the future operational strategies of Tvardi Therapeutics amid these challenging circumstances. Investors should stay informed and consider their avenues for action as this investigation progresses.